PubMed Trending Research Digest — October 03, 2026

Automated digest · 95 articles · 15 research areas · October 03, 2026

Overview

Across this week’s set of studies, a dominant theme is precision—moving from broad disease labels toward mechanism-informed stratification. In oncology and neuropsychiatry, large-scale genetic and biomarker efforts (e.g., exome-wide schizophrenia risk genes, TP53mono functional subclassification in MDS, spatial/temporal mapping of glioblastoma recurrence, and ctDNA MRD lead-time in colorectal cancer) emphasize that variant- and context-level biology better predicts outcomes than coarse categories. In Alzheimer’s disease, real-world performance of p-tau217 and CSF biomarker stratification for short-term lecanemab response highlight the practical need to reduce misclassification when biomarkers guide treatment.

A second major thread is immune modulation tailored to microenvironment and patient context. Multiple studies refine how and when immunotherapies work—such as checkpoint blockade persisting after lymph node dissection, metabolic control of Th9 persistence under glucose deprivation, and NK-cell “intracellular checkpoint” regulation via PTPN22. Translational and clinical efforts also focus on improving targeting and safety: low-CDC anti-CD38 strategies in high-risk myeloma, IL-2 Treg activation in early type 1 diabetes, and CAR T/B-cell depletion profiling in progressive MS. Together, these works converge on the idea that immune efficacy depends on both intrinsic immune-state regulators and extrinsic tissue constraints.

Finally, metabolic and aging biology continues to connect molecular hubs to clinical endpoints. Studies link circadian/environmental inputs to mitochondrial lipid cycling (SLC25A34), hypertension to osteoarthritis via AVP–AVPR1A signaling, and senescence targeting (dasatinib+quercetin) to improved fibrotic MASH surrogates. In parallel, incretin/glucagon-based therapies (survodutide, semaglutide) and broader diabetes care consensus updates reinforce a shift toward integrated cardiometabolic risk management with mechanistic rationale. Across infectious disease and mitochondrial proteomics, the field also advances target discovery by building experimentally grounded “parts lists” and structural/functional maps of pathogen vulnerabilities.

---

Cancer genomics, risk prediction, and biomarkers

BRIP1, a G-quadruplex DNA helicase, protects against AID-induced genomic instability by limiting R-loop accumulation.

This mechanistic study investigated how the DNA helicase BRIP1 (FANCJ) protects against activation-induced cytidine deaminase (AID)-induced genomic instability by limiting R-loop accumulation. The key finding was that BRIP1’s role in resolving DNA secondary structures (including G-quadruplexes) and controlling R-loops helps prevent AID-mediated damage that can drive genomic instability relevant to B-cell lymphoma risk. The significance is that it identifies a specific pathway—R-loop accumulation under AID activity—as a targetable mechanism linking BRIP1 function to genome stability and cancer susceptibility.

Mahboob A, Ahmad H, Fatma N et al. · Molecular medicine (Cambridge, Mass.) · (2026) · View on PubMed ↗ · Free PDF ↗

Universal versus Guideline-Directed Germline Testing in Breast Cancer: Incremental Diagnostic Yield in a Predominantly Black Population.

This retrospective study compared universal germline testing (UT) versus NCCN guideline-directed germline testing in female breast cancer patients without prior germline testing at a community-based breast center, in a predominantly Black population. UT identified additional pathogenic/likely pathogenic germline variants beyond what would have been captured by NCCN-guided testing, yielding an incremental diagnostic benefit. The findings support adopting universal germline testing in breast cancer to reduce missed hereditary cancer risk in underrepresented populations.

Velazquez K, Jeng A, Roudakova K et al. · Annals of surgical oncology · (2026) · View on PubMed ↗

End-to-end deep learning methods for genetic risk prediction of schizophrenia.

Using whole exome sequencing data from 6,135 schizophrenia cases and 6,245 controls, the study evaluated end-to-end genome interpretation neural network models for genetic risk prediction of schizophrenia. Nonlinear neural networks outperformed conventional additive (linear) genetic risk models when sample size was sufficient, indicating improved capture of complex genetic effects such as epistasis. This supports next-generation, non-additive polygenic risk modeling approaches that could improve schizophrenia risk stratification.

Verplaetse N, Moreau Y, Raimondi D · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study.

This study analyzed 97 patients with acute myeloid leukemia (AML) treated with azacitidine plus venetoclax (Aza/Ven) in the prospective HM-SCREEN-Japan 02 cohort using targeted next-generation sequencing of 53 genes, cytogenetics, and clinical variables. Somatic mutations were stratified into clonal “type 1” (e.g., FLT3, PTPN11, WT1, IDH1/2, NPM1, NRAS) versus “type 2” (e.g., GATA2, KRAS, TP53, RUNX1, STAG2, ASXL1, ZRSR2, TET2) groups, and the abstract indicates heterogeneous response linked to these genomic determinants. These findings support using targeted NGS-based genomic context to better predict Aza/Ven response and refine precision treatment selection in genetically diverse AML patients.

Ueda T, Fukushima K, Chi S et al. · PloS one · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer.

This study applied cfChIP-seq (chromatin immunoprecipitation of cell-free nucleosomes with active histone marks followed by sequencing) to 441 plasma samples from individuals with advanced small cell lung cancer (SCLC), other neuroendocrine carcinomas, non-SCLC cancers, and healthy controls, integrating plasma profiles with matched tumor transcriptomes from 73 samples. Plasma cfChIP-seq profiles were used to infer tumor burden and molecular subtypes, enabling molecular classification without relying on limited tumor biopsies, particularly at relapse. The scientific significance is that cfChIP-seq provides a biopsy-sparing, plasma-based approach to track SCLC heterogeneity and potentially guide subtype-specific therapeutic strategies.

Fialkoff G, Takahashi N, Sharkia I et al. · The Journal of clinical investigation · (2026) · View on PubMed ↗ · Free PDF ↗

Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience.

This prospective observational INTERCEPT cohort study evaluated the prognostic value and lead time of longitudinal circulating tumor DNA (ctDNA) detection for minimal residual disease (MRD) in stage II–IV colorectal cancer receiving curative-intent treatment. The key finding is that MRD detection retains prognostic significance, including beyond 12 months after surgery, and the study estimates how early ctDNA positivity can provide lead time at different testing timepoints. Clinically, this supports using tissue-informed ctDNA assays for MRD surveillance to improve risk stratification and potentially guide earlier intervention after curative treatment.

Maddalena G, Aziz K, Sun R et al. · Gut · (2026) · View on PubMed ↗

Ubiquitin chain editing promotes p97/VCP-dependent removal of RPA from DNA.

This study investigated how ubiquitin signaling regulates replication protein A (RPA) on single-stranded DNA in human cells, focusing on ubiquitin chain editing and p97/VCP-dependent extraction. It showed that RPA stimulates the deubiquitinase ZUP1 to remove K63 linkages from branched K48–K63 ubiquitin chains on RPA, remodeling the ubiquitin signal after DNA damage and promoting p97/VCP-dependent removal of RPA from ssDNA. The results define a specific ubiquitin-editing mechanism that controls ssDNA factor dynamics during DNA repair.

Drake M, Zhou X, McStea A et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

Oral peri-implant tissue as a neoplastic bed: a systematic review of clinicopathology, pathogenesis, and survival outcomes.

This systematic review evaluated peri-implant neoplasia (PIN)—neoplasms adjacent to dental implants—by synthesizing clinicopathology, proposed pathogenesis, and survival outcomes from studies published through December 2025. Using PRISMA-guided methods (PROSPERO CRD42024586140), it summarized evidence on the clinical spectrum, risk factors, pathogenetic mechanisms, and outcomes reported in case reports/series and cross-sectional studies. Clinically, the review supports earlier recognition and more informed management of peri-implant neoplasia by consolidating current evidence on its drivers and prognosis.

Krishna R, Basu SN, S M et al. · Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery · (2026) · View on PubMed ↗ · Free PDF ↗

Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms.

The study analyzed pretreatment samples from 4,505 patients with myelodysplastic neoplasms (MDS) to functionally classify monoallelic TP53 (TP53mono) mutations and refine prognostic stratification. Functional heterogeneity among TP53mono variants (dominant-negative, loss-of-function, or gain-of-function) explained variable clinical outcomes, improving risk prediction beyond simply labeling mutations as TP53mono versus TP53multiHit. Clinically, this supports variant-level functional annotation of TP53mono mutations to better guide prognosis and potentially treatment decisions in MDS.

Streuer A, Ochi Y, Hutter S et al. · Blood · (2026) · View on PubMed ↗ · Free PDF ↗

Loss of the tumor suppressor p53 generates a signaling gradient that drives epithelial clonal expansion.

The study investigated how loss of tumor suppressor p53 (TP53) drives epithelial clonal expansion using mouse epidermis models. It found that p53 normally suppresses clonal expansion by limiting progenitor self-renewal, and that a p53-dependent secreted signaling network with direct targets Sfrp1, Lrp1, and Usp22 is required for the most upstream control of progenitor renewal and differentiation. This mechanistic map explains how p53 loss can create a signaling gradient that promotes tumor-like expansion, identifying candidate nodes for therapeutic targeting.

Gan Q, Li W, Lex RK et al. · Science (New York, N.Y.) · (2026) · 1 citations · View on PubMed ↗

Genomic alterations and treatment define spatiotemporal patterns of glioblastoma recurrence.

This Cancer Discovery study mapped spatiotemporal genomic alterations of glioblastoma recurrence by performing histology-guided sampling and single-cell spatial transcriptomics of surgical margin and adjacent recurrent tumor regions, with matched primary tumors from 40 patients. The surgical margin formed a distinct wound-healing microenvironment, and recurrence included a mesenchymal-enriched “stromal” malignant state associated with early TP53 mutation and spatial enrichment at the margin. These results are clinically important because they link specific molecular states and spatial niches at the resection margin to recurrence biology, potentially guiding margin-targeted therapies and surveillance strategies.

Artzi SB, Harwood DSL, Locallo A et al. · Cancer discovery · (2026) · View on PubMed ↗ · Free PDF ↗

Analysis of Rare Coding Variation Identifies New Genetic Contributors to Schizophrenia.

This study analyzed rare coding variation in a large schizophrenia cohort (87,959 cases and 150,587 controls) using exome-wide association methods. It identified 16 genes at exome-wide significance (including SETD1A, ZMYM2, HERC1, RB1CC1, SCAF1, XPO7, SP4, FYN, PPP3CA, CUL1, HDAC9, JARID2, ATP9A, PTK2, STAG1, and SCN2A) and showed that ultra-rare damaging variants are enriched in constrained genes with consistent effects across ancestries. The results expand the catalog of schizophrenia risk genes and support shared neurodevelopmental mechanisms relevant for genetic risk prediction and downstream biology.

Sealock JM, Dowd C, Liao C et al. · bioRxiv : the preprint server for biology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

---

Immunotherapy and immune checkpoint modulation

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

This clinical study (SUNRAY-02) studied olomorasib, a selective KRAS G12C inhibitor, combined with immunotherapy in patients with stage II–III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. The key finding reported in the abstract framing is that there is an unmet need for approved therapies in this early-stage KRAS G12C population, and olomorasib has demonstrated antitumor activity and manageable safety in KRAS G12C-mutant metastatic NSCLC with preclinical evidence that KRAS G12C inhibition can reverse KRAS-mediated immune suppression. The trial is clinically significant because it tests a targeted immunotherapy strategy aimed at preventing recurrence in an early-stage, genetically defined NSCLC subgroup.

Chaft J, Lee JM, Senan S et al. · Future oncology (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

This pooled analysis from the International Neoadjuvant Melanoma Consortium evaluated 5-year survival outcomes in 1,038 patients with resectable stage IIIB–D melanoma treated with neoadjuvant immune checkpoint inhibitors (anti–PD-1 regimens), BRAF/MEK inhibitors, or PD-1 plus targeted therapy. Across treatment strategies, long-term survival varied by regimen and by clinical/histopathological/molecular subgroups, with updated pooled estimates reported for postsurgical management implications. The results refine expectations for durable benefit after neoadjuvant therapy and help guide selection of neoadjuvant approaches in melanoma.

Long GV, Pires da Silva I, Perry KA et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.

This narrative review summarizes how immune checkpoint inhibitors (ICIs) have progressed from early clinical promise to more durable impact while highlighting limitations including immune-related adverse events (irAEs), resistance, and insufficient predictive biomarkers. It emphasizes emerging phenotype-driven and steroid-sparing strategies to manage toxicity without compromising antitumor efficacy and discusses mechanisms of primary and acquired resistance involving tumor-intrinsic factors, immune microenvironment changes, and host determinants. The significance is that it frames current translational priorities for improving ICI safety, durability, and biomarker-guided patient selection.

Hajjar J, Stephen B, Aaroe AE et al. · Journal of immunotherapy and precision oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).

This phase II randomized controlled trial evaluated toripalimab consolidation (an anti–PD-1 immune checkpoint inhibitor) versus observation in patients with limited-stage small cell lung cancer (LS-SCLC) after completing concurrent chemoradiotherapy (CCRT). The key finding was that adding toripalimab consolidation improved outcomes compared with observation, with efficacy and safety assessed over the consolidation period (up to 6 months) and follow-up. Scientifically and clinically, it supports integrating PD-1 blockade after CCRT to improve survival in LS-SCLC.

Zhang P, Wang D, He W et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy.

This study investigated PTPN22 (protein tyrosine phosphatase non-receptor type 22) as an intracellular checkpoint in natural killer (NK) cells by integrating single-cell RNA-sequencing and TCGA analyses with CRISPR-mediated PTPN22 knockout and pharmacologic inhibition across NK cell platforms. The key finding was that PTPN22 functionally regulates NK-cell cytotoxicity and cytokine production, and targeting PTPN22 enhances NK-cell anti-tumor activity. This provides a mechanistic rationale for developing PTPN22-directed strategies to improve NK-cell–based immunotherapies.

Uong TNT, Yoon M, Nguyen NPNM et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

This open-label, parallel-controlled randomized phase 3 trial compared felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone in patients with relapsed or refractory multiple myeloma, with emphasis on Chinese patients with 1q21+ disease. Felzartamab was engineered to retain antibody-dependent cellular cytotoxicity/phagocytosis while markedly attenuating complement-dependent cytotoxicity (CDC), aiming to reduce CDC-associated infusion reactions and preserve efficacy. The results are clinically relevant because they test whether a lower-CDC anti-CD38 monoclonal antibody can improve outcomes in a high-risk myeloma subgroup where CDC-reliant mechanisms may underperform.

He H, Shang J, Wang Y et al. · The Lancet. Haematology · (2026) · View on PubMed ↗

Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy.

This Immunity study developed and used a TCR rapid assembly platform (T-RAP) to functionally evaluate thousands of T cell receptor–peptide–MHC (TCR-pMHC) pairs under standardized conditions. Systematic testing showed that only about 50% of TCRs matched previously reported reactivity, enabling more reliable in silico TCR reactivity prediction when paired with these functional ground truths. The work is important for improving computational TCR specificity prediction for immunotherapy and vaccine design by correcting performance estimates with large-scale functional validation.

Menzel L, Zhou H, Baish JW et al. · Immunity · (2026) · View on PubMed ↗ · Free PDF ↗

Functional evaluation of TCR-pMHC pairs at scale allows in silico TCR reactivity prediction.

This Immunity study examined how the glucose-deprived tumor microenvironment affects adoptively transferred T helper 9 (Th9) cells, focusing on Th9 persistence and senescence. Glucose deprivation activated AMP-activated protein kinase (AMPK), driving Th9 senescence and loss of effector function, while restoring glucose suppressed senescence and improved persistence. These findings are clinically significant because they identify a metabolic control axis (glucose–AMPK–downstream ZAK/NF-κB signaling) that could be targeted to enhance Th9-based adoptive cell therapy in solid tumors.

Messemaker M, Kwee BPY, Moravec Ž et al. · Immunity · (2026) · View on PubMed ↗ · Free PDF ↗

Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence.

This Immunity study investigated whether immune checkpoint blockade (ICB) responses persist after surgical removal of tumor-draining lymph nodes (tdLNs) in melanoma patients and in orthotopic murine melanoma and mammary carcinoma models. The authors found that PD-1 blockade efficacy remained after regional lymph node dissection, and in mice distant lymph nodes compensated by acquiring cancer-derived antigen via redirected interstitial fluid. The results are significant because they suggest that ICB can remain effective even when tdLNs are resected, informing surgical and immunotherapy planning.

Fu J, Pei S, Du J et al. · Immunity · (2026) · View on PubMed ↗

Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review.

This JAMA Oncology review assessed treatment intensification strategies for the “poorly chemosensitive” subset of advanced high-grade serous ovarian cancer that shows insufficient platinum response and often fails to achieve complete cytoreductive surgery. The authors synthesized evidence for chemosensitization approaches—particularly in the context of modern first-line regimens incorporating bevacizumab and PARP inhibitors—and discussed emerging strategies aimed at improving tumor response before maintenance therapy. The review is significant because it frames how to overcome the two “red flags” population to increase the likelihood of minimal residual disease and better outcomes.

You B, Clamp A, Moore KN et al. · JAMA oncology · (2026) · View on PubMed ↗

Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma.

This multicenter retrospective study evaluated associations between immune checkpoint inhibitor (ICI)–based multimodal downstaging therapy before liver transplant (LT) and posttransplant oncologic outcomes and acute rejection in patients with hepatocellular carcinoma (HCC) initially beyond the Milan criteria. The key finding was that an ICI-based pretransplant strategy was associated with posttransplant outcomes while also requiring careful consideration of acute rejection risk. Clinically, the results inform how to balance tumor control from ICI-based downstaging with transplant immunologic safety in patients who are not initially eligible for LT.

Ong M, He K, Wang F et al. · JAMA oncology · (2026) · View on PubMed ↗

DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab.

This preprint evaluated whether baseline DLL3 expression measured by immunohistochemistry (IHC) predicts response and long-term outcomes in small cell lung cancer patients treated with tarlatamab, a DLL3-targeting T-cell engager. Higher baseline DLL3 IHC levels were associated with better clinical outcomes and longer-term prognosis after tarlatamab (specific effect sizes truncated in the provided abstract). The work is clinically important because it proposes a practical biomarker to enrich for patients most likely to benefit from tarlatamab and to guide future DLL3-targeted strategies.

Zhang B, Hong L, Wang K et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cell therapy and engineered immune cells

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis.

This preprint reported immune profiling after treatment with anti-CD19 CAR T cells in two adult participants with treatment-refractory progressive multiple sclerosis (mivocabtagene autoleucel, miv-cel) given intravenously after preconditioning. The authors observed post-infusion immune changes relevant to B-cell depletion beyond peripheral anti-CD20 limitations, with detailed immune profiling outcomes described in the full text (truncated in the provided abstract). The study is significant as early translational evidence that DLL3-independent, CD19-directed CAR T therapy may reshape CNS-relevant immune compartments in progressive MS.

Gupta S, Seshadri MR, Dandekar R et al. · medRxiv : the preprint server for health sciences · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmunity and targeted immunomodulation

Helios is critical for Treg effector differentiation in adipose autoimmunity.

This mouse study investigated the role of the transcription factor Helios in regulatory T cells (Tregs) in adipose autoimmunity, focusing on Helios deletion and downstream effector Treg differentiation. Helios-deficient Tregs accumulated in adipose tissue and showed an enhanced effector Treg phenotype (CD62Llo Tcf1lo) but failed to progress to terminally differentiated effector Tregs in adipose tissue, coinciding with lipodystrophy, hepatic steatosis, insulin resistance, and CD8+ T cell–mediated adipocyte destruction. The results identify Helios as a key regulator of adipose-resident Treg effector maturation, informing mechanistic targets for autoimmune metabolic disease.

Thornton AM, Chen X, Cao W et al. · The Journal of experimental medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Regulatory T cells in autoimmune liver diseases.

This review summarizes evidence on regulatory T cells (Tregs) across autoimmune liver diseases (AILDs) including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and IgG4-related sclerosing cholangitis. The key finding is that Treg abundance, phenotype, and function differ by disease and by anatomical compartment (peripheral versus hepatic), reflecting heterogeneous immune dysregulation. The clinical significance is that compartment- and disease-specific Treg biology may help stratify patients and identify more precise immunomodulatory targets.

Chen S, Zhang H, Huang H et al. · Gut · (2026) · View on PubMed ↗ · Free PDF ↗

ATF6 contributes to cardiac macrophage polarization and metabolic reprogramming following myocardial ischemia/reperfusion injury.

This mechanistic animal study examined how activating transcription factor 6 (ATF6) regulates cardiac macrophage polarization and metabolic reprogramming after myocardial ischemia/reperfusion (I/R) injury using wild-type and ATF6 knockout (ATF6-/-) mice. The key finding was that loss of ATF6 altered endoplasmic reticulum stress signaling and shifted cardiac macrophage phenotypes and metabolic programs in ways that affected tissue repair and post-I/R injury outcomes. These results identify ATF6 as a potential therapeutic target to modulate macrophage-driven repair after myocardial injury.

Wu Z, Mo S, Huang Z et al. · Metabolism: clinical and experimental · (2026) · View on PubMed ↗

Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial.

This double-blind, multicentre, randomized, placebo-controlled phase 2b trial tested low-dose interleukin-2 (IL-2) regimens in people aged 6–35 years with newly diagnosed type 1 diabetes (DIABIL-2). Low-dose IL-2 was designed to selectively activate regulatory T cells (Tregs) to preserve residual pancreatic β-cell function and identify an optimal dosing schedule. If effective, this approach could provide an immunomodulatory disease-modifying therapy early in type 1 diabetes by restoring Treg-mediated immune regulation.

Rosenzwajg M, Hartemann A, Halbron M et al. · The lancet. Diabetes & endocrinology · (2026) · 1 citations · View on PubMed ↗

Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2).

This prospective, single-arm, multicentre phase 2b study (LUMINA 2) evaluated the Bruton tyrosine kinase inhibitor rilzabrutinib, with or without concomitant corticosteroids, in adults with warm autoimmune haemolytic anaemia. The trial assessed safety and clinical activity outcomes to determine whether rilzabrutinib can improve haemoglobin and disease control through multi-immune modulation. These data are important for expanding targeted treatment options in a rare disease where current therapies can be limited by incomplete responses and toxicity.

Cooper N, Kuter DJ, Frederiksen H et al. · The Lancet. Haematology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration and neuroinflammation

In vivo detection of pathologic α- synuclein and TDP-43 in the skin and olfactory mucosa of a patient with Parkinson’s disease-like phenotype carrying the p.Thr272Serfs*10 GRN mutation.

This case report studied in vivo detection of pathological α-synuclein and TDP-43 in skin and olfactory mucosa of a patient with a Parkinson’s disease-like phenotype carrying the GRN p.Thr272Serfs*10 mutation. The key finding was that seed amplification assay and tissue analyses suggested mixed co-pathology of TDP-43 and α-synuclein, supporting a combined approach to characterize underlying neuropathology. The scientific significance is that it demonstrates feasibility of peripheral tissue sampling plus seed amplification to investigate neurodegenerative mechanisms in GRN mutation carriers.

Caroppo P, Aprea V, Villa C et al. · Molecular neurodegeneration · (2026) · View on PubMed ↗ · Free PDF ↗

A human-induced pluripotent stem cell-derived spheroid model to investigate myelin injury and repair.

The study developed a human induced pluripotent stem cell (iPSC)-derived spheroid model enriched with mature, myelinating oligodendrocytes and functionally reactive microglia to study myelin injury and repair. The model reproduced key steps of human central nervous system remyelination after a demyelinating insult, including myelin fragmentation, microglial reactivity and phagocytosis of myelin debris, oligodendrocyte differentiation, and axonal ensheathment with newly formed myelin. This provides a reproducible human platform for testing candidate remyelination therapies and dissecting cellular mechanisms of repair.

Ramesan S, Mason J, Kumar SS et al. · Nature neuroscience · (2026) · View on PubMed ↗ · Free PDF ↗

Dual effect of α-synuclein disease variants on condensate formation.

The study investigated how Parkinson’s disease–associated α-synuclein variants affect biomolecular condensate formation, focusing on specific variants including E46K and E83Q. It found that some PD-associated α-synuclein variants fail to form condensates, while disease-associated variants such as E46K and E83Q enhance condensate formation, demonstrating a dual effect on phase separation. These findings link variant-specific condensate behavior to synucleinopathy mechanisms and may help explain differential disease risk and aggregation pathways.

Chandran A, Agarwal A, Wang T et al. · Nature communications · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

The accessory makes the drug: ASO-delivered siRNA enters the human CNS for ALS.

This Cell Stem Cell piece discusses a first-in-human strategy using an antisense oligonucleotide (ASO) tag to deliver SOD1-targeting siRNA to the central nervous system (CNS) in ALS. The key point is that ASO-delivered siRNA can enter the human CNS, potentially enabling faster and more extensive SOD1 lowering with improved tolerability. This is clinically significant because it supports the feasibility of CNS-directed RNA interference for ALS patients carrying SOD1 as a therapeutic target.

Guo W, Ichida JK · Cell stem cell · (2026) · View on PubMed ↗

Short-term efficacy and safety of tavapadon for Parkinson’s disease: An exploratory systematic review and meta-analysis of randomized clinical trials.

This exploratory systematic review and meta-analysis assessed short-term efficacy and safety of tavapadon, a selective dopamine D1/D5 receptor partial agonist, in patients with Parkinson’s disease using randomized clinical trials. The key finding was the pooled effect of tavapadon on motor outcomes (via MDS-UPDRS components) and the overall safety profile across included RCTs. If confirmed in larger trials, these results could position tavapadon as an alternative symptomatic therapy with potentially different adverse-effect and motor-complication tradeoffs.

Campos TS, Pereira PS, Pires Marques ME et al. · Parkinsonism & related disorders · (2026) · View on PubMed ↗ · Free PDF ↗

Sex-specific mechanisms of chronic pain.

This Review synthesized evidence for sex-specific mechanisms underlying chronic pain across conditions such as irritable bowel syndrome, endometriosis, menstrual migraine, fibromyalgia, osteoarthritis, and neuropathic pain. It highlights that sex hormones, immune–neural cross-talk, the gut microbiome, and endogenous analgesic circuits can differentially initiate, amplify, and resolve pain in women versus men. Scientifically, it supports incorporating sex as a biological variable to improve mechanistic understanding and to guide more tailored pain therapies.

Venkataraman A, Midavaine É, Ingraham HA · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Impaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives.

This study examined whether impaired control of Epstein-Barr virus (EBV)–driven autoimmunity increases pediatric multiple sclerosis (POMS) risk by analyzing CNS-specific antibodies in 548 EBNA-1-seropositive and 30 EBNA-1-seronegative pediatric-onset MS patients versus 578 matched controls. CNS-specific antibodies were significantly more prevalent in EBNA-1-seropositive patients, supporting a link between EBNA-1–associated autoreactivity and pediatric MS susceptibility even when EBV serostatus varies. Clinically, the findings strengthen the rationale for EBV/EBNA-1–targeted risk stratification and for monitoring autoimmune antibody profiles in children at risk for MS.

Vietzen H, Waubant EL, Casper TC et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression.

This review synthesized evidence on spinal cord involvement in multiple sclerosis (MS), covering how spinal cord pathology is assessed from diagnosis through disease progression and how spinal cord MRI limitations affect clinical and trial use. The authors highlighted characteristic spinal cord MRI lesion features and integrated advances in pathophysiology and imaging to explain why spinal cord measures are underused despite their prognostic value for disability. Scientifically, the review supports improved spinal cord imaging and trial endpoints to better capture disease progression in both relapsing and progressive MS.

Koren TJ, Dugal J, Wang D et al. · Journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Timing of Deep Brain Stimulation and Cognitive Trajectories in GBA1-Associated Parkinson’s Disease.

This multicenter cohort study evaluated how the timing of deep brain stimulation (DBS) relative to Parkinson’s disease (PD) onset affects cognitive trajectories in people with GBA1-associated PD, comparing different GBA1 variant classes and non-carriers. The key finding (as framed by the study objective) is that DBS timing is associated with differences in cognitive outcomes across GBA1 variant groups rather than a uniform effect. Clinically, this supports tailoring DBS decision-making and counseling in GBA1 carriers based on when DBS is performed.

Asimakidou E, Avenali M, Aasly JO et al. · Movement disorders : official journal of the Movement Disorder Society · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimaging, neurocognitive outcomes, and brain structure

Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers.

This retrospective Mayo Clinic study analyzed clinical factors associated with discordant plasma phosphorylated tau 217 (p-tau217) results versus established Alzheimer’s disease biomarkers in participants enrolled in memory and aging studies. It identified patient/clinical characteristics linked to false-positive or false-negative p-tau217 outcomes relative to confirmatory biomarker status. The findings help reduce misclassification risk when using p-tau217 to guide AD diagnosis and treatment decisions.

Shir D, Algeciras-Schimnich A, Piura YD et al. · Neurology · (2026) · View on PubMed ↗

Baseline CSF tau and short-term clinical change during lecanemab therapy: A prospective real-world cohort study in Japan.

This prospective real-world cohort study examined whether baseline cerebrospinal fluid (CSF) biomarkers—phosphorylated tau 181 (pTau181), total tau, and Aβ42/Aβ40 measured with the Lumipulse G system—predict 6-month clinical change in 50 Japanese patients with early Alzheimer’s disease spectrum treated with lecanemab. Baseline CSF tau and/or amyloid-related measures were associated with subsequent change in Clinical Dementia Rating Sum of Boxes (CDR-SB) over 6 months (with models adjusted for age, sex, baseline MMSE and sensitivity analyses including APOE ε4). These results support using CSF biomarker stratification to anticipate short-term response to lecanemab in routine clinical settings.

Takahashi R, Kashibayashi T, Fujita J et al. · Alzheimer’s & dementia (Amsterdam, Netherlands) · (2026) · View on PubMed ↗ · Free PDF ↗

FreeSurfer-based amygdala subfield volumetry in long COVID and ME/CFS: clinical and immunological correlations.

This prospective study compared amygdala subfield volumes measured from high-resolution 3-T MRI using FreeSurfer in 27 patients with long COVID, 38 patients with ME/CFS, and 47 healthy controls, and tested clinical and immunological correlations. Amygdala subfield volumetry showed disease-associated differences and correlated with clinical severity and immunological indices (including autoantibodies and plasmablast-related measures; details truncated). The work is important because it links limbic neuroanatomy to immune and symptom profiles, potentially informing differential diagnosis and mechanistic understanding of long COVID versus ME/CFS.

Kimura Y, Sato W, Shigemoto Y et al. · Frontiers in neurology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular disease and interventional cardiology

Effects of high-dose supplemental oxygen therapy on pulmonary haemodynamics at 3250 m in high-altitude residents at risk for pulmonary hypertension.

This open-label sequential trial studied the effects of high-dose supplemental oxygen therapy on pulmonary haemodynamics in Kyrgyz high-altitude residents (>2500 m) at risk for high-altitude pulmonary hypertension (HAPH), using echocardiography under ambient air and after oxygen exposure. The key finding was that supplemental oxygen altered systolic pulmonary artery pressure (sPAP) and related haemodynamic measures, helping distinguish the contribution of reversible hypoxic vasoconstriction versus more fixed vascular remodeling in chronically exposed residents. Clinically, this informs whether oxygen therapy is likely to provide meaningful haemodynamic benefit in high-altitude populations at risk for pulmonary hypertension.

Vella A, Müller J, Omuralieva A et al. · BMJ open respiratory research · (2026) · View on PubMed ↗ · Free PDF ↗

Drug coated balloon vs. drug eluting stent in calcified de novo coronary lesions: Long term outcomes from the SPARTAN registry.

This retrospective registry analysis from the SPARTAN registry compared long-term outcomes of drug-coated balloon (DCB) versus drug-eluting stent (DES) strategies in patients undergoing percutaneous coronary intervention (PCI) for operator-reported angiographically calcified de novo coronary lesions. The key finding was that DCB and DES had comparable long-term clinical outcomes in this calcified de novo lesion population (with differences assessed over extended follow-up). Clinically, it supports the use of DCB as a stent-less alternative in selected calcified de novo lesions when long-term outcomes are a priority.

Natarajan R, Corballis N, Merinopoulos I et al. · The American journal of cardiology · (2026) · View on PubMed ↗

Hypertension fuels osteoarthritis through neuroendocrine signaling.

The study tested whether hypertension accelerates osteoarthritis (OA) through neuroendocrine signaling in human cohorts and hypertensive mouse models. It found that OA-primed chondrocytes up-regulate arginine vasopressin receptor 1A (AVPR1A), making them responsive to circulating AVP elevated in hypertension, and that AVP–AVPR1A signaling promotes cartilage catabolism while suppressing anabolic regulators. The significance is identification of a hypertension–AVP–AVPR1A pathway that could be targeted to slow OA progression in patients with elevated blood pressure.

Kim SJ, Kim HE, Chung KH et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Updated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation.

This systematic review and meta-analysis studied whether percutaneous left atrial appendage closure (LAAC) versus oral anticoagulation reduces stroke, bleeding, and mortality in nonvalvular atrial fibrillation, incorporating new randomized evidence from CHAMPION-AF and CLOSURE-AF. The analysis pooled effects and stratified outcomes by bleeding risk, anticoagulation eligibility, and comparator to determine where LAAC provides benefit or harm. Scientifically and clinically, the updated pooled estimates refine patient selection for LAAC as an alternative to long-term anticoagulation.

Pekyi-Boateng PK, Mahadevan A, Frimpong SK et al. · Stroke · (2026) · View on PubMed ↗

---

Thrombosis, hemostasis, and platelet biology

Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack.

This prospective observational quality-improvement project evaluated implementation of rapid CYP2C19 genotyping to guide antiplatelet selection in patients with secondary prevention ischemic stroke or transient ischemic attack across three comprehensive stroke centers. Patients underwent rapid CYP2C19 testing and received a P2Y12 inhibitor (clopidogrel or ticagrelor) based on results, addressing real-world barriers such as timely and understandable genotype reporting. The study’s clinical significance is that it operationalizes CYP2C19-guided therapy to improve antiplatelet effectiveness in routine care where clopidogrel response varies by genotype.

Smith DM, Ramos Ramos P, Ashena S et al. · Clinical pharmacology and therapeutics · (2026) · View on PubMed ↗

Inhibition of mitochondrial permeability transition selectively suppresses thrombogenic platelet procoagulant activity.

The study examined whether selectively inhibiting mitochondrial permeability transition pore (mPTP) opening can suppress agonist-driven, thrombogenic platelet procoagulant activity in platelets. Inhibition of mPTP selectively reduced sustained calcium influx–dependent mitochondrial depolarization and the commitment to phosphatidylserine (PS)-high procoagulant states, thereby lowering platelet thrombogenic activity while preserving hemostatic PS exposure. This suggests an mPTP-targeted strategy as a more pathway-specific antithrombotic approach than cyclophilin-targeting agents that can have pleiotropic effects.

Zhang Y, Sandler J, Owegie OC et al. · Blood · (2026) · View on PubMed ↗

---

Metabolic disease, obesity, and incretin-based therapies

Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies.

This review studied how diabetic “panvascular” disease is driven by metabolic reprogramming in vascular cells under hyperglycaemia, insulin resistance, and dyslipidaemia. It found that these diabetic conditions rewire core metabolic pathways—such as diverting glucose through the polyol, hexosamine, and AGE–PKC axes, promoting lipotoxicity, and disrupting amino-acid metabolism—thereby contributing to cardiovascular, cerebrovascular, renal, retinal, and peripheral vascular complications. The work is significant because it frames metabolic pathway nodes as therapeutic targets, supporting development of mechanism-based strategies rather than treating each complication separately.

Bai Y, Bai Y, Liu S · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology.

This review synthesizes contemporary cardiovascular outcome evidence for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism, focusing on trials in type 2 diabetes and in people with established cardiovascular disease and overweight/obesity without diabetes. It reports that long-acting GLP-1RAs reduce major adverse cardiovascular events (MACE in multiple studies), while SELECT (semaglutide) and SOUL (oral semaglutide) support cardiovascular benefit and SURPASS-CVOT shows tirzepatide noninferiority to dulaglutide without superiority. The clinical significance is guiding cardiology practice on which incretin-based therapies confer cardiovascular protection beyond glucose lowering.

Li M · Frontiers in cardiovascular medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.

This translational preclinical study tested the dual glucagon receptor/glucagon-like peptide-1 receptor agonist survodutide in a mouse model of hypertension-accelerated diabetic kidney disease induced by adeno-associated virus–mediated renin overexpression (ReninAAV) in uninephrectomized diabetic db/db mice. The key finding was that survodutide conferred nephroprotective effects, consistent with improved renal function and reduced kidney injury in this advanced DKD model. These results support further clinical development of survodutide as a potential therapy for diabetic kidney disease with impaired renal GCGR signaling.

Hamilton A, Thisted L, Ougaard M et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling.

The study examined how circadian rhythms, diet, and temperature signals are integrated in adipocytes to control mitochondrial lipid cycling via the orphan transporter SLC25A34. It showed that the adipocyte clock suppresses Slc25a34 during the sleep phase through REV-ERB transcriptional repressors, while active-phase cues (lipid-rich diet, cold exposure, and lipolytic signals) relieve repression and stimulate Slc25a34 transcription via peroxisome proliferator-activated receptors. The findings position SLC25A34 as a molecular hub linking environmental inputs to mitochondrial substrate import (proposed oxaloacetate transport), with implications for metabolic regulation.

Karavaeva I, Basse AL, Trammell SAJ et al. · Science (New York, N.Y.) · (2026) · 1 citations · View on PubMed ↗

Sex-biased expression of enteroendocrine cell-derived hormones contributes to higher fat storage in Drosophila females.

This eLife study investigated how sex-biased expression of enteroendocrine (EE) cell–derived hormones contributes to higher fat storage in female Drosophila. The authors identified that EE hormones—including peptides such as Allatostatin A (AstA), Allatostatin C (AstC), neuropeptide F (NPF), tachykinin (Tk), Diuretic hormone 31 (Dh31), Bursicon, CCHamide 1/2, and short neuropeptide F—show sex-biased regulation that drives female-specific fat storage phenotypes. The work is significant because it connects gut endocrine signaling to sex-specific metabolic outcomes, offering a mechanistic model for how hormonal regulation can produce dimorphic energy storage.

Biswas P, Rideout EJ · eLife · (2026) · View on PubMed ↗ · Free PDF ↗

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

This multinational, double-blind phase 3 trial studied once-weekly survodutide (a dual glucagon receptor–GLP-1 receptor agonist) in adults with type 2 diabetes and obesity (BMI ≥27). Survodutide produced clinically meaningful improvements in weight and metabolic outcomes over the trial period compared with randomized control arms (details truncated in the provided abstract). These findings support survodutide as a potential next-generation incretin/glucagon-based therapy for improving cardiometabolic risk in people with coexisting obesity and type 2 diabetes.

Wharton S, le Roux CW, Startseva E et al. · The New England journal of medicine · (2026) · View on PubMed ↗

GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytes.

This study investigated how the TGF-β superfamily ligand GDF3 regulates adipocyte signaling in the ActE-ALK7/ACVR2 pathway, focusing on ActE (INHBE)-driven control of adipocyte lipolysis. GDF3 was identified as the principal endogenous antagonist of ActE/ALK7 signaling, with human transcriptomic data showing coordinated regulation in obesity. These findings suggest a new endogenous brake on INHBE/ALK7-mediated metabolic dysfunction that could help reconcile human versus mouse phenotypes in MASLD/MASH biology.

Kotikalapudi N, Ramachandran D, Zhou EY et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Liver disease, transplantation, and hepatology

Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.

This prospective multicenter study evaluated 1-year survival after liver transplantation (LT) in adults with decompensated cirrhosis with acute-on-chronic liver failure (ACLF), specifically comparing outcomes for ACLF-2 and ACLF-3 patients who underwent LT versus those declined for LT. The key finding was that mortality within 1 year was very high among patients declined for LT (73% for ACLF-2 and 88% for ACLF-3), highlighting the severity of these groups. Scientifically and clinically, the study clarifies the survival impact of LT decision-making in ACLF-2/ACLF-3 and supports evidence-based transplant evaluation.

Gustot T, Bernal W, Fernández J et al. · Journal of hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Kidney disease and renal biomarkers

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

In a 52-week randomized placebo-controlled trial in people with type 2 diabetes and chronic kidney disease, investigators tested whether subcutaneous semaglutide 1 mg weekly preserves kidney function and explored mechanisms using integrated multiparametric kidney MRI, kidney biopsy histology, and single-nucleus and spatial transcriptomics. Semaglutide treatment was associated with better kidney outcomes than placebo and was accompanied by kidney-specific mechanistic signals across imaging, histology, and transcriptomic profiles. These data strengthen the scientific rationale for GLP-1 receptor agonist therapy to slow CKD progression in type 2 diabetes and identify potential biological pathways mediating benefit.

Tuttle KR, Bjornstad P, Smith C et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond the Threshold: Continuous Creatinine Change and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke.

This secondary analysis of the CAN-REST registry studied whether continuous early creatinine change within 48 hours after endovascular thrombectomy (EVT) provides graded prognostic information beyond dichotomous contrast-associated acute kidney injury (CA-AKI) definitions in 6,638 EVT-treated adults with acute ischemic stroke. The key finding is that subthreshold creatinine changes (not captured by threshold-based CA-AKI) still convey prognostic signal for outcomes, indicating a dose-like relationship. This supports moving from binary CA-AKI definitions to continuous kidney-function trajectories to better risk-stratify patients after EVT.

Schwarz G, Cascio Rizzo A, Ambler G et al. · Stroke · (2026) · View on PubMed ↗

---

Infectious disease mechanisms and pathogen biology

A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies.

This study used a selective small-molecule inhibitor, PZL-26, to target the mitochondrial protease LONP1 and examined consequences for mitochondrial proteostasis and oxidative phosphorylation (OXPHOS) dependencies. Using PZL-26 in a whole-genome CRISPR-Cas9 screen, the authors identified genes required for survival under LONP1 inhibition, consistent with proteomics results and implicating LONP1 in complex I biogenesis, mitochondrial transcription, and translation. Scientifically, it validates LONP1 as a druggable mitochondrial vulnerability and maps genetic dependencies that could inform targeted cancer or mitochondrial-disorder strategies.

Szilagyi Z, Michon P, Pardo-Hernández C et al. · Life science alliance · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial proteome of the apicomplexan Babesia divergens.

This study characterized the mitochondrial proteome of the apicomplexan parasite Babesia divergens by enriching mitochondria and performing protein mass spectrometry, generating a high-confidence inventory (BdMitoCarta) of nuclear-encoded mitochondrial proteins. The authors identified 525 mitochondrial proteins and found broad conservation of the B. divergens mitoproteome across Apicomplexa. This resource is scientifically significant because it supports functional annotation of mitochondrial biology in Babesia and can inform target discovery for therapies such as atovaquone-related pathways.

Betsinger CN, Calvo SE, Mian SY et al. · Current biology : CB · (2026) · View on PubMed ↗ · Free PDF ↗

Acanthamoeba ATP synthase structure reveals the TCA cycle is tethered to OXPHOS.

The study used cryo-electron microscopy of unenriched mitochondrial lysate plus mass spectrometry proteomics to resolve endogenous mitochondrial ATP synthase (complex V) and related factors in the protozoan pathogen Acanthamoeba castellanii. Acanthamoeba ATP synthase was captured in an IF1-inhibited state and showed how Acanthamoeba-specific subunits/extensions stabilize the OXPHOS ATP synthase while tethering the TCA cycle to oxidative phosphorylation. This structural linkage clarifies how divergent mitochondrial architecture in Acanthamoeba couples carbon metabolism to ATP production, informing potential parasite-specific metabolic vulnerabilities.

Fry MY, Luce BE, Stefely JA et al. · Cell · (2026) · 3 citations · View on PubMed ↗ · Free PDF ↗

Comparative analysis of mitochondrial proteomes across the tree of life.

This work compared experimentally defined mitochondrial proteomes from the MitoCarta Tree of Life project across eight organisms to infer mitochondrial evolution and identify pathogen-specific components. It identified 8,619 mitochondrial proteins in 3,199 families (with 43% lacking Pfam domains) and reported 33 conserved protein families present in eukaryotic pathogens but absent in humans, then retrained a protein-language-model classifier to predict mitoproteomes of ~200 eukaryotes. These findings provide an evolution-informed, experimentally grounded target shortlist for protozoan infectious diseases and a scalable computational framework for mitoproteome prediction.

Chen MZ, Stefely JA, Bardon EG et al. · Cell · (2026) · 7 citations · View on PubMed ↗ · Free PDF ↗

Conserved and divergent mitochondrial assemblies in kinetoplastid parasites.

The study integrated complexome profiling with cryo-electron microscopy to define conserved versus lineage-specific mitochondrial macromolecular assemblies in kinetoplastid parasites Leishmania tarentolae and Trypanosoma brucei. It found that respiratory, metabolic, RNA-processing, and other complexes differ by species and life stage in abundance/composition, and structures of L. tarentolae respiratory complex III2 (CIII2), complex IV2 (CIV2), and complex V (CV) refined mitochondrial complex annotations. This improves mechanistic understanding of how kinetoplastid mitochondria evolve and function across life stages, supporting more accurate parasite-specific bioenergetic models.

Solayman M, Liao YT, Calvo SE et al. · Molecular cell · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

ZNFX1, an immunoregulatory RNA helicase and E3 ubiquitin ligase, assembles into pleiomorphic polymers.

Researchers determined cryo-EM structures of RNA-bound and RNA-free ZNFX1, an SF1-family RNA helicase and E3 ubiquitin ligase, to understand how ZNFX1 mutations cause recurrent infections. They found auto-inhibition of the helicase-associated ATPase via a regulatory insertion that occludes the RNA-binding groove, and showed ZNFX1 uses an RZ finger (RNF213-like) plus a Miz-like domain as a bi-catalytic E3 to ubiquitylate substrates, with ubiquitin chains further enhancing activity. These mechanistic insights connect patient mutations to disrupted RNA sensing/helicase regulation and ubiquitin ligase function, informing innate-immunity therapeutic strategies.

Naydenova K, Mund T, Yip MCJ et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

Reciprocal cross-species infection potential of human and domestic cat hepatitis B viruses.

The study tested reciprocal cross-species infection potential between human hepatitis B virus (HBV) and domestic cat hepatitis B virus (DCHBV) by using transfection-based assays in Huh7 cells and examining determinants of host specificity. It found that DCHBV infectious clones could be produced in human cells and evaluated how receptor-binding motifs and the cognate receptor NTCP influence cross-species transmission, including effects of co-transfection with hepatitis delta virus (HDV). These data clarify whether DCHBV can utilize human entry pathways, informing the feasibility of cat HBV as a model for HBV biology and host-tropism studies.

Wu Q, Beer A, Xu Z et al. · Hepatology (Baltimore, Md.) · (2026) · View on PubMed ↗

Phage proteases activate CBASS antiphage immunity.

The study investigated how phage infection activates CBASS (cyclic oligonucleotide-based antiphage signaling systems) in bacteria. It reconstituted CBASS recognition of bacteriophage T4 in vitro and identified that phage prohead protease activity triggers CD-NTase activation by proteolytically cleaving a CD-NTase activation loop, enabling immune nucleotide signal synthesis in vivo. This reveals a general, protease-driven mechanism for switching on bacterial antiphage immunity and clarifies how CD-NTase sensors are regulated during infection.

Hobbs SJ, Kranzusch PJ · Science (New York, N.Y.) · (2026) · View on PubMed ↗

The mycomembrane proteins PorH and ProtX are inserted at polar growth zones and linked to the cell wall.

The study investigated how mycolate outer membrane proteins (MOMPs) PorH and ProtX are assembled in the bacterium Corynebacterium glutamicum, focusing on their insertion at polar growth zones and linkage to the cell wall. The authors found that PorH and ProtX are inserted specifically at polar growth sites and are functionally connected to cell-wall architecture, implicating envelope assembly at growth poles in MOMP positioning. This mechanistic insight advances understanding of how mycomembrane pore proteins are built in Mycobacteriales-like cell envelopes, informing strategies to disrupt nutrient uptake in related pathogens such as Mycobacterium tuberculosis.

Hart EM, de Bruin DA, Marando VM et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

The diverse functions of viral microproteins.

This preprint systematically investigated viral microproteins by constructing a >50,000-element small ORF library across human-infecting viruses and screening for functional activity using phenotype-first approaches. The study identified >2,000 active viral microproteins that modulate host pathways through diverse mechanisms, supported by downstream profiling methods including Perturb-seq, mass spectrometry, AI-guided structure prediction, and mechanistic assays. The resulting atlas provides a scalable resource for discovering microprotein functions and understanding viral evolution and host-pathway manipulation.

Chen-Neumann YH, Grauvogel L, Zhang AS et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

TurboID proximity labeling reveals protein interaction networks for germline Argonautes.

This preprint used TurboID proximity labeling to map protein interaction networks of germline Argonaute proteins (CSR-1, PRG-1/Piwi, PPW-2/WAGO-3, WAGO-1, WAGO-4, and HRDE-1 as a comparator) in C. elegans. It found that CSR-1 and WAGO-4, despite targeting overlapping sets of germline genes and sharing 22G-small RNA binding, have distinct proximal interaction networks. The study is significant because it clarifies how closely related Argonautes can drive different regulatory complexes, informing mechanisms of small RNA–mediated gene regulation in germ granules.

Fuentes-Otalora S, Del Borrello S, Irshaid II et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome and host–microbe interactions

Fusobacterium nucleatum enhances enterotoxigenic Bacteroides fragilis-mediated neuron loss and intestinal motility dysfunction.

Using mouse colonization models, the study examined how Fusobacterium nucleatum modulates enterotoxigenic Bacteroides fragilis (ETBF)–mediated neuron loss and intestinal motility dysfunction. ETBF toxin (BFT) induced apoptosis of colonic myenteric neurons via the NOD1–RIPK2–CASP9–CASP3 pathway, and this neuron loss and dysmotility persisted after ETBF clearance, with human cohort analyses linking higher ETBF and F. nucleatum abundance to disease. The work mechanistically connects specific gut microbes and a defined host signaling cascade to long-term enteric neuropathy and motility impairment, suggesting targets for microbiome-driven GI complications.

Zhang Y, Zhao Y, Zhang L et al. · Nature microbiology · (2026) · View on PubMed ↗

Importance of faecal sample collection in prospective cohort studies to evaluate the effect of the gut microbiome on cancer development.

This methodological paper assessed the importance of fecal sample collection in prospective cohort studies designed to test whether the gut microbiome causally influences cancer development. The key finding was that prospective designs require standardized, pre-diagnosis fecal sampling with sufficient sample sizes and incident cancer ascertainment to detect robust microbiome–cancer associations. Scientifically, it provides guidance for designing microbiome studies that move beyond cross-sectional correlations toward causal inference.

Vogtmann E, Um CY, Zouiouich S et al. · The Lancet. Microbe · (2026) · View on PubMed ↗ · Free PDF ↗

---

Aging, senescence, and biological clocks

Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All-Cause Mortality.

This study investigated multimodal ageing biomarkers and plasma proteomic signatures for association with 16-year all-cause mortality in the Lothian Birth Cohort 1936 (LBC1936) using Cox regression (861 participants; 444 deaths). It found that proteomic “organ clocks” derived from plasma proteomics can be benchmarked against established multimodal ageing biomarkers to quantify links with mortality risk. The scientific significance lies in improving biological-age measurement and strengthening mortality prediction beyond chronological age.

Pyrgioti M, Eguiagaray IM, Redmond P et al. · Aging cell · (2026) · View on PubMed ↗

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.

In a phase 2, double-blind, randomized, placebo-controlled trial, participants with fibrotic metabolic dysfunction-associated steatohepatitis (MASH) received intermittent senolytic therapy with dasatinib (100 mg/day) plus quercetin (1,000 mg/day) or placebo. Dasatinib+quercetin improved senescence-related and clinical surrogate endpoints compared with placebo over 3 weeks of intermittent dosing (repeated across the treatment period). These results provide proof-of-principle that targeting cellular senescence with D+Q may be a therapeutic strategy for human fibrotic MASH.

Koning M, Kovynev A, Fondevila MF et al. · Nature metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

Reframing menopause and menopause hormone therapy as opportunities for healthy aging.

This Review evaluated how menopause characteristics (type, timing, and symptom burden) and the heterogeneity of menopause hormone therapy (over 200 formulations differing in estrogen/progestogen dose and timing) affect health outcomes across the postmenopausal lifespan. It concludes that both menopause biology and therapy formulation/timing have distinct risk–benefit profiles that are often overlooked in research and clinical practice. The work reframes menopause and menopause hormone therapy as opportunities for healthy aging by emphasizing more personalized, mechanism-informed management.

Gravelsins LL, Perović M, Alexander MW et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

X and Y chromosomes as determinants of aging and disease.

This Review assessed how sex chromosomes (XX vs XY) contribute to aging and disease through cell-autonomous gene dosage and regulatory differences beyond gonadal hormones. It integrates mechanisms including X-chromosome inactivation/escape, X reactivation, parent-of-X effects, X skewing, Y-linked gene functions, and age-associated Y loss, linking them to immunity, neurodegeneration, cancer, and cardiometabolic disease. The significance is a shift toward sex-chromosome biology as a driver of disease trajectories, informing more precise models and potential interventions.

Dubal DB, Ambrosio F, Stout MB et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

---

Clinical trials, guidelines, and health services research

Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

This consensus report studied updated, holistic management recommendations for non-pregnant adults with type 2 diabetes, targeting multidisciplinary diabetes care teams in the USA and Europe. It found that evidence published since the 2022 ADA/EASD update supports broadening care beyond glycaemic control to include lifestyle interventions and management of multiple long-term comorbid risks. The update is clinically significant because it provides an integrated, evidence-based framework to guide real-world treatment decisions across cardiometabolic and other diabetes-related complications.

Davies MJ, Aroda VR, Bajaj M et al. · Diabetologia · (2026) · View on PubMed ↗

Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

This consensus report studied updated management guidance for nonpregnant adults with type 2 diabetes, convened by the American Diabetes Association and the European Association for the Study of Diabetes for healthcare teams in the USA and Europe. It found that a systematic review of literature since 2022 supports shifting emphasis from hyperglycaemia-only strategies toward holistic management of type 2 diabetes and its risk of multiple long-term conditions. The recommendations are scientifically and clinically significant because they standardize care pathways for complex, multi-morbidity risk in routine practice.

Davies MJ, Aroda VR, Bajaj M et al. · Diabetes care · (2026) · View on PubMed ↗ · Free PDF ↗

Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency.

These consensus guidelines studied diagnosis and management of primary pyruvate dehydrogenase complex deficiency (PDCD), a monogenic disorder caused by pathogenic variants in pyruvate dehydrogenase complex subunit/regulatory genes, across clinical settings. The key finding was that patient reports show substantial international variability in emergency and outpatient management despite a broad phenotype spectrum from early congenital lactic acidosis to childhood-onset developmental delay with epilepsy and attenuated adult neurological presentations. The guidelines are clinically significant because they aim to standardize care for a rare genetic disease with highly variable presentation and treatment practices.

Keshavan N, Neugebauer J, Bellusci M et al. · Journal of inherited metabolic disease · (2026) · View on PubMed ↗ · Free PDF ↗

Safety and functional efficacy of transperineal laser ablation in large prostates (>80 mL): a prospective single-center study.

This prospective single-center study evaluated the safety and functional efficacy of transperineal laser ablation (TPLA) in men with large benign prostatic glands (>80 mL), using transrectal ultrasound guidance and outpatient procedures under local anesthesia (± oral benzodiazepines). The key finding was that in 85 included patients, TPLA was performed with a median total energy of 10,000 J (IQR 9000–12,000) using 3–4 fibers per case, and the study focused on perioperative and catheter-related outcomes plus mid-term efficacy. The results are clinically significant because they inform procedural risk/benefit and expected functional outcomes for TPLA in the challenging “very large prostate” population.

Conte FL, Saladino M, Lambertini L et al. · Minerva urology and nephrology · (2026) · View on PubMed ↗

Migraine 1-2-3-4-5: a candidate communication aid for adult migraine without aura.

This correspondence studied the development of “Migraine 1-2-3-4-5,” a candidate communication aid for adults (≥18 years) with recurrent migraine without aura. It found that reorganizing selected ICHD-3 positive clinical features into five numerical anchors spanning symptom category, headache features, a 4–72-hour duration condition, and at least five attacks could provide a compact structure for discussing migraine history. The significance is practical: it may improve patient–clinician communication and recognition of migraine features in under-recognized cases.

Zhang Y, Guo Z, Lin C et al. · The journal of headache and pain · (2026) · View on PubMed ↗ · Free PDF ↗

Surgical steps and relevant anatomical landmarks for the implantation of an inflatable penile prosthesis reservoir placed in the retropubic and submuscular abdominal (“ectopic”) space.

This educational and technical study described step-by-step surgical implantation of an inflatable penile prosthesis reservoir placed in the retropubic and submuscular abdominal “ectopic” space, using predissected anatomical specimens and body-donor training within a postgraduate masterclass program. The authors focused on identifying relevant anatomical landmarks and standardizing the surgical steps for this challenging reservoir placement. The work supports safer, more consistent surgical training for erectile dysfunction patients undergoing inflatable penile prosthesis implantation.

Osmonov D, Heinze T, Wilson SK et al. · International journal of impotence research · (2026) · View on PubMed ↗

Irritable bowel syndrome.

This Nature Reviews Disease Primers article synthesized current evidence on irritable bowel syndrome (IBS), a prevalent gut–brain interaction disorder affecting an estimated 4–11% of the global population. It highlights IBS heterogeneity and emphasizes dysregulated bidirectional communication within the gut–brain axis, including roles for altered motility, visceral hypersensitivity, epithelial barrier dysfunction, neuroimmune activation, and the gut microbiome. The review provides a clinically oriented framework for understanding mechanisms and guiding future diagnostics and therapies for IBS.

Chang L, Corsetti M, Chey WD et al. · Nature reviews. Disease primers · (2026) · View on PubMed ↗

Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.

This article describes the phase III AIRTIVITY trial design evaluating verducatib (BI 1291583), a dipeptidyl peptidase 1/cathepsin C inhibitor, in adults with bronchiectasis. The key finding is the planned randomized, placebo-controlled study structure (approximately 1680 adults, with additional pediatric enrollment noted in the truncated abstract) to assess efficacy, safety, and tolerability based on prior phase II AIRLEAF results showing reduced pulmonary exacerbation risk. Clinically, the trial design aims to test whether targeting chronic neutrophilic inflammation with verducatib improves outcomes in bronchiectasis at scale.

Chalmers JD, Shteinberg M, Chotirmall SH et al. · ERJ open research · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.

This study compared durability of complete response (DoR) in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS) treated with TAR-200 versus nadofaragene firadenovec, using reconstructed individual patient data digitized from SunRISe-1 cohort 2 and NCT02773849 Kaplan–Meier curves. The key finding was that complete response durability differed between the two gene-therapy approaches, with TAR-200 showing a more durable complete response pattern than nadofaragene firadenovec among CR responders (as inferred from the reconstructed DoR curves). These results support selecting bladder-preserving therapy based on response durability when radical cystectomy is unfit or declined.

Fukushima H, Yoshida S, Yajima S et al. · Anticancer research · (2026) · View on PubMed ↗

Deprescribing Olanzapine After Cancer-Related Symptoms Resolve: Insights From A Two-Case Series.

This two-case series described deprescribing olanzapine in cancer survivors after cancer-related symptoms resolved, focusing on patients previously treated for supportive care indications such as chemotherapy-induced nausea/vomiting, anorexia, insomnia, and anxiety. The key finding was that olanzapine could be tapered/discontinued after symptom resolution without recurrence of the target symptoms in these cases. The clinical significance is that it offers practical, real-world guidance for deprescribing olanzapine in survivorship to reduce metabolic risks from prolonged exposure.

Amoateng MD, Bruera E, Reddy A · Journal of pain and symptom management · (2026) · View on PubMed ↗

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.

This phase 2b randomized trial evaluated the intranasal live attenuated pertussis vaccine BPZE1 in healthy children aged 6–17 years, comparing BPZE1 alone versus BPZE1 with tetanus-reduced diphtheria-acellular pertussis vaccine (Tdap) and including placebo and active controls in children primed with acellular pertussis vaccines. BPZE1 induced immunogenicity consistent with mucosal immune responses (nasal secretory IgA) while demonstrating an acceptable safety profile across study arms. These findings support further development of BPZE1 as a strategy to improve mucosal protection against Bordetella pertussis in children who previously received acellular pertussis vaccines.

Faust SN, Céspedes J, Avila L et al. · The Lancet. Infectious diseases · (2026) · View on PubMed ↗ · Free PDF ↗

Enhanced liver regeneration via targeted mRNA delivery for partial in vivo reprogramming.

This Cell Reports Medicine study investigated whether targeted mRNA delivery enabling transient partial in vivo reprogramming using Yamanaka factors (OSKM: Oct4, Sox2, Klf4, c-Myc) can enhance liver regeneration. Transient OSKM induction generated liver progenitor-like cell populations without injury and with limited activation of injury-associated immune responses, supported by single-nucleus RNA sequencing. The approach is significant because mRNA-based, time-limited reprogramming may reduce safety concerns associated with prolonged transgenic/viral OSKM expression while promoting regenerative repair.

Jo BK, Song YS, Song W et al. · Cell reports. Medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer.

This real-world comparative effectiveness study used US claims/registry data to compare outcomes of abiraterone, apalutamide, enzalutamide, and docetaxel doublets plus androgen-deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). It evaluated progression-free survival (PFS) and overall survival (OS) with follow-up through June 2025 for patients initiating ADT within 4 months of diagnosis and starting one of the specified therapies within 4 months of ADT initiation. The results provide practical, head-to-head effectiveness estimates that can inform treatment selection outside clinical trial settings.

Nwogu IB, Kreif N, Khan HM et al. · JCO oncology practice · (2026) · View on PubMed ↗ · Free PDF ↗

Effects of dietary supplements on lower-limb power and jump performance in physically active individuals and athletes: a systematic review and Bayesian network meta-analysis.

This systematic review and Bayesian network meta-analysis evaluated the effects of dietary supplements on lower-limb peak power (PP), relative peak power (RPP), vertical jump (VJ), and countermovement jump (CMJ) in randomized controlled trials and crossover trials involving physically active individuals and athletes. Across separate Bayesian random-effects networks, the authors compared relative supplement effects and assessed certainty and robustness of findings for jump and power outcomes. Scientifically and practically, the work helps rank supplements by evidence strength for performance-related metrics, guiding more evidence-based supplement selection for training and competition.

Sun R, Su M, Xu X et al. · Journal of the International Society of Sports Nutrition · (2026) · View on PubMed ↗ · Free PDF ↗

Decision-making in paediatric palliative sedation: A vignette survey across five European countries.

This vignette survey studied how physicians across five European countries make decisions about initiating and managing pediatric palliative sedation therapy (PST) in two end-of-life scenarios. The survey found substantial variability in physician responses and procedures, with only about 55.6% of respondents meeting the study’s criteria for appropriate decision-making/management (as reported in the truncated abstract). The findings are significant because they underscore the need for clearer international guidance and training to standardize pediatric PST decision-making.

Ferri Perez A, Robijn L, Beernaert K et al. · European journal of pediatrics · (2026) · View on PubMed ↗

AGA Clinical Practice Update on Surveillance of Pancreatic Cystic Lesions and Hepatocellular Carcinoma in Older Adults: Expert Review.

This AGA Clinical Practice Update reviewed surveillance approaches for pancreatic cystic lesions (PCLs) and hepatocellular carcinoma (HCC) specifically in older adults, motivated by rising numbers of patients over age 60 with incidentally detected PCLs and increasing prevalence of cirrhosis in metabolic dysfunction–associated steatohepatitis. The key contribution is an expert framework for tailoring surveillance intensity and decision-making to older adults’ risk profiles and competing health considerations. Clinically, it aims to improve benefit–harm balance by aligning surveillance recommendations with the evolving epidemiology of aging-related risk for PCL malignancy and HCC.

Das KK, Serper M, Vege SS · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · (2026) · View on PubMed ↗ · Free PDF ↗

Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.

This systematic review evaluated how patients with difficult-to-treat (DTT) inflammatory bowel disease (IBD)—defined as active disease despite exposure to advanced therapies with ≥2 different mechanisms of action—were included and represented in randomized controlled trials of advanced therapies in ulcerative colitis and Crohn’s disease. Across included RCTs, inclusion and participation of DTT-IBD patients were heterogeneous and insufficiently defined, limiting interpretability for this high-need subgroup. The review highlights a need for more consistent trial eligibility criteria and reporting so that advanced-therapy evidence better reflects real-world DTT-IBD populations.

Parigi TL, Solitano V, Mekonnen HD et al. · Alimentary pharmacology & therapeutics · (2026) · View on PubMed ↗

Pheochromocytoma Across the Perioperative Course: Current Concepts and Clinical Management.

This article reviewed current concepts and clinical management of pheochromocytoma across the perioperative course in patients undergoing surgical treatment. It emphasizes that diagnosis requires biochemical confirmation of catecholamine excess followed by imaging localization, and that perioperative care should involve a multidisciplinary team with careful antihypertensive management to prevent complications. The review is clinically significant because timely recognition and coordinated perioperative treatment reduce risk of target-organ damage such as cardiomyopathy, stroke, and diabetes.

Mirrakhimov AE, Bashall N · Anesthesiology research and practice · (2026) · View on PubMed ↗ · Free PDF ↗

Predicted 10-year cardiometabolic risk among hospital staff: a cross-sectional study.

This retrospective cross-sectional study used a localized digital risk assessment platform and machine-learning–based modeling to estimate predicted 10-year cardiometabolic risk among hospital staff in Taiwan, focusing on occupational subgroups exposed to shift work, high stress, and irregular schedules. The analysis identified high-risk occupational groups for conditions such as hypertension, type 2 diabetes, stroke, and cardiovascular disease. The findings are significant for precision occupational health interventions aimed at targeting modifiable workplace risk factors and preventing cardiometabolic disease.

Wu CY, Wu YW, Wu HY et al. · Frontiers in public health · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on October 03, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.